BAM
FOLD

Belpointe Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Belpointe Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,172
Closed -$102K – 1554
2023
Q1 		$102K Buy
9,172
+8,348
+1,013% +$103K 0.01% 1297
2022
Q4 		$10.1K Buy
+824
New +$9.28K ﹤0.01% 2616

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Belpointe Asset Management's FOLD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 9,172 shares — an estimated $102K sold.

Belpointe Asset Management first reported a position in FOLD in Q4 2022 and held it in 2 quarters. The position peaked at $102K in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 9,172 Amicus Therapeutics shares in Q2 2023, an estimated $102K.
  • Belpointe Asset Management first reported a position in Amicus Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Amicus Therapeutics position peaked at $102K in Q1 2023.
  • 216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.